众生药业(002317.SZ)发布上半年业绩，归母净利润1.88亿元，同比增长114.96%

Core Viewpoint - Zhongsheng Pharmaceutical (002317.SZ) reported a decline in revenue for the first half of 2025, while net profit saw significant growth, indicating a mixed performance in financial results [1] Financial Performance - The company achieved operating revenue of 1.3 billion yuan, a year-on-year decrease of 4.74% [1] - The net profit attributable to shareholders of the listed company was 188 million yuan, reflecting a year-on-year increase of 114.96% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 187 million yuan, showing a year-on-year growth of 7.42% [1] - Basic earnings per share were reported at 0.22 yuan [1]